Last reviewed · How we verify

NCT05083650

Large Macular Hole Closure Rate With Amniotic Membrane Graft With and Without Limitorrhexis

Status unknown NA Last updated 19 October 2021
What this trial tests

NA trial testing Macular hole closure with amniotic membrane with/without internal limiting membrane peeling in Macular Holes in 16 participants. Status unknown.

Timeline
10 March 2021
Primary endpoint
10 December 2022
10 March 2023

Quick facts

Lead sponsorInstituto de Oftalmología Fundación Conde de Valenciana
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment16
Start date10 March 2021
Primary completion10 December 2022
Estimated completion10 March 2023
Sites1 location across Mexico

Drugs / interventions tested

Conditions studied

Sponsor

Instituto de Oftalmología Fundación Conde de Valenciana — full company profile →

Who can join

Adults 40 to 90, any sex, with Macular Holes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with idiopathic macular holes (MHs) postoperative closure rates for large MHs (diameter \> 550 μm) are disappointing and often require a second intervention, different techniques have been described with very variable success rates in different published studies, an efficient technique with good functional outcome has not been found.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Macular Holes

Currently open trials in the same condition.

Other Instituto de Oftalmología Fundación Conde de Valenciana trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05083650.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing